Ipca's bulk drug receives nod for use in China

New Delhi, Dec 29 (UNI) Mumbai-based Ipca Laboratories Ltd today said the State Food and Drug Administration of China has approved and registered the company's Active Pharmaceutical Ingredient (API) Atenolol for import and use in the country.

It is the first such registration received by the company from China for sale of its API. The company has plans to register more APIs in China.

The company is also marketing formulations of Atenolol in various markets of CIS, Asia, Africa and Europe.

The company is engaged in the manufacturing and marketing of a range of pharmaceuticals with a strong thrust on exports.

Ipca's exports to over 100 countries contributed about 53 per cent of its total income of Rs 753 crore in the financial year 2005-06.

UNI CS DKS DS1610